Idiopathic Pulmonary fibrosis (IPF) is a subset of interstitial lung diseases, where in the normal ageing of lung is augmented. It is characterised by fibrosis of the lung architecture which ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Low total cholesterol levels were tied to an increased risk of death for pulmonary fibrosis patients with disease of unknown cause in a study.

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current ...

Management said the new name, logo, website and branding elements ... The biotech’s lead drug candidate is a potential treatment for idiopathic pulmonary fibrosis (IPF) that it picked up through ...

Discover the connection between genetic risk factors for idiopathic pulmonary fibrosis and the development of post-COVID-19 ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

The patients' lungs got better. The importance of this finding is that pulmonary fibrosis after COVID-19 tends to resolve, while in idiopathic pulmonary fibrosis (IPF) it always progresses.